J&J gains monthly dosing approval for Rybrevant Faspro

Posted on by wpadmin
  • The U.S. FDA has granted approval for a monthly dosing of Johnson & Johnson’s (JNJ) Rybrevant Faspro (amivantamab and hyaluronidase) for EGFR-mutated advanced non-small cell lung cancer.
  • The treatment was previously approved for biweekly subcutaneous administration.
  • Rybrevant Faspro is taken

Leave a Reply

Your email address will not be published. Required fields are marked *